Geometric approaches to assessing the numerical feasibility for conducting matching‐adjusted indirect comparisons.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 974, doi. 10.1002/pst.2210
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2022 AND VI 21 AND IP 5
Results: 21
1
2
Estimation of treatment effects in short‐term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1037, doi. 10.1002/pst.2214
- By:
- Publication type:
- Article
3
A two‐stage adaptive clinical trial design with data‐driven subgroup identification at interim analysis.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1090, doi. 10.1002/pst.2208
- By:
- Publication type:
- Article
4
A flexible mixed‐data model applied to claims data for post‐market surveillance of prescription drug safety behavior.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1022, doi. 10.1002/pst.2213
- By:
- Publication type:
- Article
5
A treatment‐specific marginal structural Cox model for the effect of treatment discontinuation.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 988, doi. 10.1002/pst.2211
- By:
- Publication type:
- Article
6
A practical guide to sample size calculations: Installation of the app SampSize.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1109, doi. 10.1002/pst.2215
- By:
- Publication type:
- Article
7
SCI: A Bayesian adaptive phase I/II dose‐finding design accounting for semi‐competing risks outcomes for immunotherapy trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 960, doi. 10.1002/pst.2209
- By:
- Publication type:
- Article
8
Confidence intervals for point‐of‐stabilization of content uniformity.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 944, doi. 10.1002/pst.2207
- By:
- Publication type:
- Article
9
Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1005, doi. 10.1002/pst.2212
- By:
- Publication type:
- Article
10
Assessment of pharmacokinetic linearity after repeated drug administration.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 932, doi. 10.1002/pst.2206
- By:
- Publication type:
- Article
11
The importance of using ordinal scores for patient classification based on health‐related quality of life trajectories.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 919, doi. 10.1002/pst.2205
- By:
- Publication type:
- Article
12
Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 865, doi. 10.1002/pst.2198
- By:
- Publication type:
- Article
13
Bayesian adaptive randomization design incorporating propensity score‐matched historical controls.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1074, doi. 10.1002/pst.2203
- By:
- Publication type:
- Article
14
Estimating survival parameters under conditionally independent left truncation.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 895, doi. 10.1002/pst.2202
- Publication type:
- Article
15
Estimation and expected sample size in Simon's two‐stage designs that stop as early as possible.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 879, doi. 10.1002/pst.2200
- By:
- Publication type:
- Article
16
Sample size re‐estimation for response‐adaptive randomized clinical trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 1058, doi. 10.1002/pst.2199
- By:
- Publication type:
- Article
17
Analysis of an incomplete binary outcome dichotomized from an underlying continuous variable in clinical trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 907, doi. 10.1002/pst.2204
- By:
- Publication type:
- Article
18
Pairwise joint modeling of clustered and high‐dimensional outcomes with covariate missingness in pediatric pneumonia care.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 845, doi. 10.1002/pst.2197
- By:
- Publication type:
- Article
19
Estimands in observational studies: Some considerations beyond ICH E9 (R1).
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 835, doi. 10.1002/pst.2196
- By:
- Publication type:
- Article
20
Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 818, doi. 10.1002/pst.2195
- By:
- Publication type:
- Article
21
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 5, p. 815, doi. 10.1002/pst.2137
- Publication type:
- Article